In early April, the New England Journal of Medicine (NEJM) published three independent case series of 39 patients who developed a newly described syndrome characterized by thrombosis and thrombocytopenia soon after they were vaccinated with AstraZeneca’s COVID-19 vaccine (which is not available in the United States).

On May 27, FDA expanded the indication for rimegepant (Nurtec ODT—Biohaven) to include preventive treatment in adults with episodic migraine, defined as fewer than 15 headache days per month.

Cara Aldridge Young

In today’s climate of self-management for optimal health and wellness, use of prebiotics and probiotics has become increasingly popular.

Daniel L. Krinsky, RPh, MS

Many patients with chronic pain turn to alternative, complementary therapy as part of their pain management. Acupuncture has been gaining legitimacy for decades and was approved as a medical therapy in the United States in the 1990s.

Mickie Cathers

Updates from FDA